Balanced news tone
News Sentiment
DSGN sentiment intelligence
Design Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
59
Balanced news tone
58 relevant articles
News tone and price action are not far from neutral.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-2.9% over one week, +38.5% over four weeks, trend active, and materially above fair value.
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
83/100 classification
One-week reaction
-2.9%
Price reacting lower
Trend fit
Trend active
38.5% over four weeks
Fair value
164.0%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
24
Neutral
33
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Barchart.com
Direct company coverage
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien
The Myotonic Dystrophy market is projected to reach approximately USD 89 million in 2023 and grow at an 18.4% CAGR through 2036, driven by increased disease awareness, genetic research advancements, and a robust clinical pipeline. Several companies, including Avidity Biosciences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 14:10
- Source
- Barchart.com
Stock Titan
Direct company coverage
If You Invested $1,000 in Design Therapeutics, Inc. (DSGN)
This article examines the historical performance of investing $1,000 in Design Therapeutics, Inc. (DSGN) over various periods, showing substantial gains in the last year but losses over longer terms. It also provides a detailed overview of the company, a clinical-stage biotechnol
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 04 Jul 2026 12:40
- Source
- Stock Titan
TradingView
Direct company coverage
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN
This article displays the "Price to sales forward" financial metric for Design Therapeutics, Inc. (NASDAQ: DSGN). The content includes the company's stock symbol, market, and a brief mention of the financial data period, value, and change.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 05:11
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN
This page from TradingView displays financial information for Design Therapeutics, Inc. (NASDAQ: DSGN), specifically focusing on its forward price-to-earnings ratio. The content indicates that the market was closed at the time of access, with no trades occurring. The page also li
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 03 Jul 2026 03:09
- Source
- TradingView
Simply Wall Street
Direct company coverage
Design Therapeutics (Nasdaq:DSGN) - Stock Analysis
This article provides a stock analysis of Design Therapeutics (DSGN), highlighting its current market performance, risk factors, and pipeline developments. The company, a clinical-stage biopharmaceutical firm focusing on genetic diseases, shows significant stock growth over the p
- Tone
- Positive 61/100
- Event
- Market update
- Published
- 01 Jul 2026 12:10
- Source
- Simply Wall Street
Investing.com
Direct company coverage
Cantor Fitzgerald reiterates Design Therapeutics stock rating
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 01 Jul 2026 07:00
- Source
- Investing.com
Investing.com Canada
Direct company coverage
Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com
Design Therapeutics (NASDAQ:DSGN) has initiated patient dosing for its DT-818 drug in a Phase 1 clinical trial for adults with myotonic dystrophy type-1, leading to a 6.7% surge in its stock. The company anticipates reporting data from this trial in 2027 and continues to advance
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 30 Jun 2026 23:10
- Source
- Investing.com Canada
Stock Titan
Direct company coverage
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause
Design Therapeutics (Nasdaq: DSGN) has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC small molecule, for adults with myotonic dystrophy type-1 (DM1). DT-818 is designed to address the underlying genetic cause of DM1 by selective
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 30 Jun 2026 23:10
- Source
- Stock Titan
Investing.com
Direct company coverage
Design Therapeutics begins dosing DM1 drug in phase 1 trial
Design Therapeutics (NASDAQ:DSGN) has commenced patient dosing in a Phase 1 clinical trial for DT-818, a potential treatment for myotonic dystrophy type-1 (DM1). The company's stock surged on the news, having already seen significant gains over the past year. DT-818 is designed t
- Tone
- Positive 78/100
- Event
- Market update
- Published
- 30 Jun 2026 12:41
- Source
- Investing.com
Investing.com Australia
Direct company coverage
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com
Design Therapeutics Inc. (NASDAQ:DSGN) shares rose in premarket trading after the company announced the initiation of patient dosing in its Phase 1 trial for DT-818. This GeneTAC small molecule aims to treat myotonic dystrophy type-1 (DM1) by targeting the underlying genetic caus
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 30 Jun 2026 12:41
- Source
- Investing.com Australia
The Manila Times
Direct company coverage
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) clinical trial of DT-818, a GeneTAC® small molecule for Myotonic Dystrophy Type-1 (DM1). DT-818 is designed to address the genetic cause of DM1 by selectively reducing the transcription
- Tone
- Positive 77/100
- Event
- Market update
- Published
- 30 Jun 2026 11:41
- Source
- The Manila Times
MSN
Direct company coverage
Design Therapeutics spikes as RBC upgrades on an eventful 2026
Design Therapeutics (NASDAQ:DSGN) saw its shares rise after RBC Capital upgraded the stock, citing upcoming catalysts and a potentially "eventful" 2026. The upgrade reflects optimism about the company's future prospects and clinical developments.
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 30 Jun 2026 11:09
- Source
- MSN
marketscreener.com
Direct company coverage
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark
Design Therapeutics, Inc. (DSGN) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is among several recent updates for the company within the Russell indices, including additions to the Russell 2500 Growth Benchmark and Russell Microcap Growth Benchmar
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 29 Jun 2026 21:39
- Source
- marketscreener.com
marketscreener.com
Direct company coverage
Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark
Design Therapeutics, Inc. (NasdaqGS: DSGN) has been removed from the Russell 2000 Value Benchmark, as announced on June 29, 2026. This news comes alongside several other Russell index adjustments for the company, including being added to the Russell Small Cap Comp Growth, Russell
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 15:39
- Source
- marketscreener.com
www.marketscreener.com
Direct company coverage
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark
Design Therapeutics, Inc. (NasdaqGS: DSGN) has been added to the Russell 3000E Growth Benchmark. The company specializes in developing GeneTACT molecules—small-molecule gene-targeted chimera therapeutic candidates designed for diseases caused by inherited nucleotide repeat expans
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 08:10
- Source
- www.marketscreener.com
Sahm
Direct company coverage
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
Design Therapeutics (NASDAQ:DSGN), a loss-making company, saw its share price soar by 274% over the last year. Despite an increase in cash burn to US$54 million, the company maintains a robust cash runway of 4.1 years based on its US$223 million cash reserves. Analysts believe De
- Tone
- Positive 66/100
- Event
- Balance sheet
- Published
- 27 Jun 2026 10:40
- Source
- Sahm
TradingView
Direct company coverage
Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN)
This article provides an overview of Design Therapeutics, Inc. (DSGN) stock performance, financial estimates, and analyst forecasts. It includes details on the current stock price, volatility, market capitalization, historical highs and lows, and upcoming earnings reports, along
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 27 Jun 2026 05:10
- Source
- TradingView
TradingView
Direct company coverage
DSGN Forecast — Price Target — Prediction for 2027
This article provides an outlook on Design Therapeutics, Inc. (DSGN) stock, including analyst price targets, historical performance, and financial data. Analysts predict a max estimate of $22.00 and a min estimate of $20.00 for DSGN. The company's stock has shown significant grow
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 26 Jun 2026 08:41
- Source
- TradingView
TradingKey
Direct company coverage
Design Therapeutics Inc (DSGN) Institutional Confidence
Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry, with institutional shareholding at 61.89%, a decrease of 8.26% quarter-over-quarter. Steven Cohen is the largest institutional sharehold
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 08:11
- Source
- TradingKey
TradingKey
Direct company coverage
Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Design Therapeutics Inc (DSGN), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. As of June 18, 2026, DSGN has a price momentum score of 9.66 and is sho
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 18 Jun 2026 18:09
- Source
- TradingKey
Moomoo
Direct company coverage
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21
Oppenheimer has reiterated its Buy rating for Design Therapeutics (DSGN.US), maintaining a target price of $21. This indicates continued analyst confidence in the company's prospects.
- Tone
- Positive 76/100
- Event
- Analyst action
- Published
- 18 Jun 2026 08:11
- Source
- Moomoo
TradingKey
Direct company coverage
Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Design Therapeutics Inc (DSGN), covering its business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant data, leading the report to state that this info
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 01:10
- Source
- TradingKey
TradingKey
Direct company coverage
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Design Therapeutics Inc (DSGN), highlighting its current earnings forecast score, average price target of $12.50, and analyst ratings. Based on 7 analysts, most support a "Buy" trend for the stock. The article also touches on past an
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 17 Jun 2026 18:10
- Source
- TradingKey
Barchart.com
Direct company coverage
Why Wall Street Loves Cadence Design Systems Stock Here
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jun 2026 07:00
- Source
- Barchart.com
Market source
Direct company coverage
Is Cadence Design Systems, Inc. (CDNS) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jun 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options
Design Therapeutics (DSGN) has granted director David Shapiro 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months starting from June 9, 2026, and will be fully vested by the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 06:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55
Design Therapeutics (DSGN) director George Simeon was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months after June 9, 2026, or fully by the company's next annual st
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 04:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes
Design Therapeutics (NASDAQ: DSGN) has released the results of its 2026 Annual Meeting of Stockholders. Shareholders re-elected Simeon George, M.D. as a Class II director and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year endin
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 Jun 2026 03:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Director at Design Therapeutics (DSGN) awarded options on 30,000 shares
Design Therapeutics (DSGN) director Justin D. Gover has been granted stock options for 30,000 shares of common stock. These options have an exercise price of $10.55 per share and an expiration date of June 8, 2036. The shares will vest in equal monthly installments over 12 months
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:40
- Source
- Stock Titan